THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE), aninnovative company developing a scalable robotic platform for non-invasive echotherapy, unveils today its new plan for growth. Major milestones have been reached, preparing the launch of SONOVEIN® next generation.
Strategic achievements in 2021, allowing further developments in 2022
Theraclion’s ambition to replace the surgical act with a robotic platform for non-invasive treatment by echotherapy is in motion. In 2021, Theraclion has developed its varicose veins market, thanks to its SONOVEIN® device’s effectiveness. SONOVEIN® has thus recently expanded into new markets such as Italy and Serbia. The robotic platform is now in the hands of vascular surgery key opinion leaders in the main European markets. Moreover, in September, the FDA approved the first echotherapy for varicose veins trial in the United States. First treatments in China with SONOVEIN® are opening up possibilities within the Asian market. This strong capacity development on a global market of $10 billioni paves the way for extension to leading global health centers.
Theraclion strongly invested in the technological development of SONOVEIN®, to enable the first phase of an Artificial Intelligence (AI) pivot. The 2022 SONOVEIN® will allow technical and per-operative data collection to create deep learning image processing models. These models will then be gradually deployed in the new versions of the device along with additional data collection features. This breakthrough will be possible thanks to the unique robotic and imaging capabilities of SONOVEIN®. This innovation will thus unleash the full potential of Theraclion’s technology. The aim is to eventually deliver a universal, non-invasive, AI-assisted treatment, sparing physicians the training time and bringing an optimal quality of care to patients.
Furthermore, Theraclion is giving a new boost to its thyroid and breast cancer markets with ECHOPULSE®. In June, Theraclion indeed launched a cutting-edge research collaboration with the University of Virginia Cancer Center (USA) in breast cancer treatment with HIFU.
Finally, the recent appointment of Yann Duchesne as Executive Chairman of the Board marks a new chapter in governance. This event follows the arrival of highly experienced directors, setting the company up for success in its major strategic shift.
In 2021, Theraclion SA achieved a turnover of €1,481K, doubling its sales compared to 2020.
| Year revenue/K€ | 2021 | 2020 | Variation |
| Sales of systems | 1,059 | 277 | 282% |
| Sales of consumables | 200 | 315 | -37% |
| Sales of services | 222 | 152 | 46% |
| Total sales Theraclion SA | 1,481 | 744 | 99% |
| Out of which Thyroid and Breast | 937 | 592 | 58% |
| Out of which varicose veins | 530 | 152 | 249% |